Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2024-A00021-46 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will aim to study the heterogeneity of skin-resident mast cells and of blood circulating hematopoietic progenitors in patients suffering from isolated Cutaneous Mastocytosis and from systemic Mastocytosis with skin lesions.
Mastocytosis is a rare disease caused by abnormal mast cell accumulation/proliferation. Its clinical features are very heterogeneous. Among adult patients, 15% present an isolated cutaneous mastocytosis (CM), while 85% of them present a systemic mastocytosis (SM) with cutaneous lesions. In addition, regardless of the diagnosis (i.e., CM or SM), it is frequent to observe mast cell-dependent symptoms of variable severity, ranging from gastrointestinal discomfort to life-threatening reactions. To date, the origin of such heterogeneous manifestations in adult patients is still elusive. Researchers hypothesize that the heterogeneity in mastocytosis symptoms might originate, at least in part, from a broad diversity of mast cell populations in patients. This study will aim to uncover heterogeneity of skin-resident mast cells and of blood circulating hematopoietic progenitors in patients suffering from isolated CM or SM with skin lesions. Patients with isolated CM and patients with SM with cutaneous involvement will be recruited from the Mastocytosis Expert Center of Toulouse.
Cluster of Differentiation (CD) 45+ cells from skin biopsies and CD 34+ cells from blood will be isolated by magnetic cell sorting for scRNAseq. Bioinformatics analysis pipeline will be used in order to analyze the cellular heterogeneity of skin lesions and blood from CM and SM patients by comparing their transcriptomic signatures. Using trajectories analysis, the researchers will then deduce infer a differentiation pathway between blood progenitors and cutaneous mast cells at the patient level. Researchers will then confirm the expression of identified relevant biomarkers by highly multiplexed imaging in frozen skin biopsies from CM patients and from SM patients.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients with isolated cutaneous mastocytosis with associated skin involvement - RNAseq | Other |
| |
| patients with mastocytosis indolent systemic with associated skin involvement | Other |
| |
| patients with isolated cutaneous mastocytosis with associated skin involvement | Other |
| |
| patients with mastocytosis indolent systemic with associated skin involvement - RNAseq | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| scRNAseq | Genetic | A blood test tube (only for scRNAseq, 2 tubes of 10 ml per patient) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Study of the diversity of skin CD 45+ cells and circulating blood CD 34+ cells | This study aims to examine the diversity of CD 45+ cells in the skin and CD 34+ cells in the circulating blood in patients. The approach used will be single cell sequencing (scRNAseq) to identify the transcriptomic profiles of the different cell populations in these two types of mastocytosis. | 24 month and one week |
| Measure | Description | Time Frame |
|---|---|---|
| Study of common or differential transcripts | This part of the study will focus on analyzing common or differential genetic transcripts between patients with isolated cutaneous mastocytosis and those with systemic mastocytosis. The aim is to understand the underlying molecular differences between these two forms of the disease. | 24 month and one week |
| Measure | Description | Time Frame |
|---|---|---|
| marker | through advanced imaging techniques (multiplexed imaging), marker in patients with isolated cutaneous mastocytosis and systemic mastocytosis will be identified compared with control sample | 24 month and one week |
| marker - isolated cutaneous mastocytosis |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Cristina Bulai Livideanu, MD | Contact | 0567778138 | +33 | livideanu.c@chu-toulouse.fr |
| Name | Affiliation | Role |
|---|---|---|
| Cristina Bulai Livideanu, MD | Toulouse univiversity hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital | Toulouse | 31059 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008415 | Mastocytosis |
| ID | Term |
|---|---|
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000092386 | Single-Cell Gene Expression Analysis |
| ID | Term |
|---|---|
| D059010 | Single-Cell Analysis |
| D003584 | Cytological Techniques |
| D008919 | Investigative Techniques |
| D020869 | Gene Expression Profiling |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| two Skin biopsies | Procedure | 2 skin biopsies from a lesional area |
|
| one Skin biopsies | Procedure | 1 skin biopsies from a lesional area |
|
through advanced imaging techniques (multiplexed imaging), marker in patients with isolated cutaneous mastocytosis will be identified compared with control sample |
| 24 month and one week |
| marker - systemic mastocytosis | through advanced imaging techniques (multiplexed imaging), marker in patients with systemic mastocytosis will be identified compared with control sample | 24 month and one week |
| D000090362 | Mast Cell Activation Disorders |
| D007154 | Immune System Diseases |
| D005821 | Genetic Techniques |